Best of: The future of exercise

Episode Summary

Executive Summary: Russ Altman interviews Stanford biochemist Jonathan Long about how exercise, diet, obesity, and diabetes are linked through specific molecules. Long explains that exercise triggers measurable chemical signals like LAC-PHE, which suppresses appetite and may help explain post-workout effects. He argues exercise can be studied like medicine and that an “exercise pill” is possible someday, though likely decades away.

Main Topics: GLP-1 drugs and the rise of modern weight-loss medicine (Priority: 5/5): Long traces the success of semaglutide and related GLP-1 receptor agonists to decades of basic science and translation, using them as a model for how exercise biology might eventually yield therapies. Chemical approach to studying exercise physiology (Priority: 5/5): Long describes his lab’s strategy of using molecules as clean handles to define complex states like exercise, rather than treating exercise only as a medical or behavioral phenomenon. Discovery and role of LAC-PHE (Priority: 5/5): The conversation focuses on LAC-PHE, an exercise-induced metabolite derived from lactate that suppresses appetite, is conserved across species, and may reflect a gut-to-brain signaling axis. Motivation, psychology, and endocannabinoids (Priority: 4/5): Altman asks about exercise motivation and mental preparation; Long notes emerging evidence that endocannabinoids contribute to motivation to exercise and related psychological effects. Diabetes, obesity, and weight loss mechanisms (Priority: 5/5): Long connects obesity to type 2 diabetes and discusses how weight loss improves metabolic disease, while noting that LAC-PHE may improve diabetes indirectly by reducing body weight. Metformin’s unexpected link to exercise pathways (Priority: 5/5): Long explains that metformin also stimulates the LAC-PHE pathway, showing that a common diabetes drug and sprint exercise converge on a shared molecular mechanism. Prospects and limits of an exercise pill (Priority: 4/5): The episode ends with a nuanced discussion of whether exercise could someday be mimicked pharmacologically, with Long emphasizing that the field is still in early basic-science stages.

Key Arguments: GLP-1 drugs demonstrate that basic science can take decades to become transformative medicine, making them a model for future exercise-derived therapeutics. Exercise is not yet defined with the same molecular precision as modern medicine, but metabolites and signaling molecules may allow it to be characterized more rigorously. LAC-PHE is a conserved exercise-induced molecule that rises after high-intensity activity and suppresses appetite, likely contributing to reduced hunger after workouts. LAC-PHE lasts much longer than lactate itself in humans, suggesting it converts short exercise bouts into prolonged physiological effects. Exercise responses differ between trained and untrained people because trained individuals handle lactate better, producing a smaller spike in the pathway. Weight loss matters because excess body weight itself drives cardiometabolic risk, but ideal weight loss preserves lean mass while reducing fat mass. Metformin and sprint exercise both activate the LAC-PHE pathway, indicating unexpected mechanistic overlap between a drug and physical activity. An “exercise pill” is plausible in principle, but current understanding is still at an early foundational stage and any real therapy would likely be years or decades away.

Data Points: Exercise recommendation: 150 minutes a week - Altman references the CDC-style exercise guideline when discussing how exercise is currently prescribed. Weight-loss drug development timeline: 40 years - Long describes the journey from early GLP-1 discovery in the 1980s to today’s effective drugs. Early therapeutic signal: around 2010 - GLP-1 drugs first showed modest weight loss in people treated for diabetes. Human exercise test duration: 10 minutes - Example of a cardiopulmonary treadmill test where a person runs until stopping. Lactate recovery time: about 1 hour - In humans, lactate returns to baseline roughly one hour after acute exercise, while LAC-PHE remains elevated. LAC-PHE elevation duration: 6 hours+ - LAC-PHE stays high at six hours after exercise in humans. LAC-PHE normalization window: 12 to 18 hours - Long says LAC-PHE returns to baseline only after roughly half a day to three-quarters of a day. Comparison across species: mice, humans, racehorses, sled dogs - Long cites multiple animal and human examples showing that LAC-PHE rises across diverse moving animals. Metformin effect size: stronger inducer than sprint exercise - Long states metformin raises LAC-PHE more strongly in people than sprint exercise does.

Pivotal Quotes: "“Where we are is where the GLP-1 medicines were in the 1980s.”" — Jonathan Long: Long’s comparison of current exercise-biology research to the early days of GLP-1 drug discovery. "“Actually, these two things you think are very different. Sprinting and this anti-diabetic drug, metformin. Unbelievable. These are actually intimately, intimately connected.”" — Jonathan Long: Long describes the surprising shared pathway between exercise and metformin via LAC-PHE. "“What we ought to be able to do is understand the pathways of exercise well enough that we could develop a therapeutic that hijacks exercise pathways.”" — Jonathan Long: Long explains the rationale behind pursuing an exercise-mimicking medicine.

Implications: Listeners should see exercise, weight loss, and diabetes as chemically connected rather than separate issues. For medicine, the work points to future drugs that mimic specific exercise benefits, but only after deeper basic research identifies the relevant pathways.